4D Molecular Therapeutics, Inc. — Cyborg Score 6/10
Solid
Biotechnology - Gene Therapy
Strategic Profile
Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V.
Cyborg Score Rationale
Enrollment in 4D-150 Phase 3 wet AMD clinical trials is exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026. Recent positive clinical data supports lead program momentum, but pre-revenue status and clinical development risks warrant caution.
Top Insights
Lead program 4D-150 showing clinical efficacy for wet AMD with potential to reduce need for frequent anti-VEGF injections
Diversified pipeline across multiple therapeutic areas including cystic fibrosis (4D-710), geographic atrophy, and rare metabolic diseases
Platform technology based on directed evolution enables discovery of proprietary AAV vectors tailored to specific tissues and diseases
Recent positive interim data from 4D-710 Phase 1 cystic fibrosis trial demonstrates durable CFTR transgene expression with clinical benefits
Named Competitors
Adeno-associated virus (AAV) gene therapies — Strategic partner in ophthalmology and gene therapy development
CRISPR and gene editing therapies — Alternative genetic medicine approaches
Traditional anti-VEGF therapies — Standard of care for wet AMD and DME
Recent Developments
(January 2026) 4D-150 Phase 3 wet AMD enrollment exceeding expectations with 381 patients enrolled; 4FRONT-1 trial on track for Q1 2026 completion
(December 2025) Positive interim data from 4D-710 AEROW Phase 1 trial in cystic fibrosis showing clinically meaningful lung function improvements
(August 2024) Positive 24-week data from 4D-150 PRISM Phase 2 wet AMD trial with population extension cohort
Open the full interactive 4D Molecular Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.